NasdaqGM:CRBP

Stock Analysis Report

Executive Summary

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.

Snowflake

Fundamentals

High growth potential with excellent balance sheet.

Risks

  • Corbus Pharmaceuticals Holdings has significant price volatility in the past 3 months.

Share Price & News

How has Corbus Pharmaceuticals Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.7%

NasdaqGM:CRBP

0.6%

US Biotechs

0.8%

US Market


1 Year Return

-29.6%

NasdaqGM:CRBP

-10.2%

US Biotechs

1.9%

US Market

CRBP underperformed the Biotechs industry which returned -10.2% over the past year.

CRBP underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

CRBPIndustryMarket
7 Day-0.7%0.6%0.8%
30 Day-0.9%-0.8%3.4%
90 Day-23.8%-0.5%2.1%
1 Year-29.6%-29.6%-9.4%-10.2%4.2%1.9%
3 Year-19.8%-19.8%6.0%2.4%46.7%37.2%
5 Yearn/a5.0%-0.09%62.3%44.5%

Price Volatility Vs. Market

How volatile is Corbus Pharmaceuticals Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Corbus Pharmaceuticals Holdings undervalued based on future cash flows and its price relative to the stock market?

7.64x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Corbus Pharmaceuticals Holdings's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Corbus Pharmaceuticals Holdings's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Corbus Pharmaceuticals Holdings is loss making, we can't compare its value to the US Biotechs industry average.

Corbus Pharmaceuticals Holdings is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Corbus Pharmaceuticals Holdings, we can't assess if its growth is good value.


Price Based on Value of Assets

Corbus Pharmaceuticals Holdings is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Corbus Pharmaceuticals Holdings expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

42.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Corbus Pharmaceuticals Holdings's revenue is expected to grow significantly at over 20% yearly.

Corbus Pharmaceuticals Holdings's earnings are expected to grow significantly at over 20% yearly.

Corbus Pharmaceuticals Holdings's revenue growth is expected to exceed the United States of America market average.

Corbus Pharmaceuticals Holdings's earnings growth is expected to exceed the United States of America market average.

Corbus Pharmaceuticals Holdings's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Corbus Pharmaceuticals Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Corbus Pharmaceuticals Holdings performed over the past 5 years?

-52.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Corbus Pharmaceuticals Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Corbus Pharmaceuticals Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Corbus Pharmaceuticals Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Corbus Pharmaceuticals Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Corbus Pharmaceuticals Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Corbus Pharmaceuticals Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Corbus Pharmaceuticals Holdings's financial position?


Financial Position Analysis

Corbus Pharmaceuticals Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Corbus Pharmaceuticals Holdings's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Corbus Pharmaceuticals Holdings's level of debt (0.2%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (8.5% vs 0.2% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 759x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Corbus Pharmaceuticals Holdings has sufficient cash runway for 2.5 years based on current free cash flow.

Corbus Pharmaceuticals Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 29% each year.


Next Steps

Dividend

What is Corbus Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Corbus Pharmaceuticals Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Corbus Pharmaceuticals Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Corbus Pharmaceuticals Holdings has not reported any payouts.

Unable to verify if Corbus Pharmaceuticals Holdings's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Corbus Pharmaceuticals Holdings has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Corbus Pharmaceuticals Holdings's salary, the management and board of directors tenure and is there insider trading?

5.1yrs

Average management tenure


CEO

Yuval Cohen (44yo)

5.4yrs

Tenure

US$3,572,460

Compensation

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc  ...


CEO Compensation Analysis

Yuval's remuneration is higher than average for companies of similar size in United States of America.

Yuval's compensation has increased whilst company is loss making.


Management Age and Tenure

5.1yrs

Average Tenure

61yo

Average Age

The average tenure for the Corbus Pharmaceuticals Holdings management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.3yrs

Average Tenure

47yo

Average Age

The tenure for the Corbus Pharmaceuticals Holdings board of directors is about average.


Insider Trading

More shares have been bought than sold by Corbus Pharmaceuticals Holdings individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$8,21316 Aug 19
Craig Millian
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,500
Max PriceUS$5.48
BuyUS$9,99813 Aug 19
Barbara White
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares1,639
Max PriceUS$6.10
BuyUS$9,00013 Aug 19
Craig Millian
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,500
Max PriceUS$6.00
BuyUS$7,11612 Aug 19
Yuval Cohen
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares1,175
Max PriceUS$6.06
BuyUS$87,89412 Aug 19
Robert Discordia
EntityIndividual
Role
Chief Operating Officer
Chief Operating Officer
Shares15,000
Max PriceUS$5.86
BuyUS$10,00120 May 19
Barbara White
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares1,389
Max PriceUS$7.20
BuyUS$7,22715 May 19
Craig Millian
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,000
Max PriceUS$7.23
BuyUS$71214 May 19
Sean Moran
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares100
Max PriceUS$7.12
BuyUS$6,95514 May 19
Yuval Cohen
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares995
Max PriceUS$6.99
BuyUS$13,95818 Mar 19
David Hochman
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,000
Max PriceUS$6.98
BuyUS$6,97815 Mar 19
John Jenkins
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,000
Max PriceUS$6.98
BuyUS$34,25915 Mar 19
Craig Millian
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares5,000
Max PriceUS$6.85
BuyUS$29,99414 Mar 19
Barbara White
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares4,638
Max PriceUS$6.47
BuyUS$10,00514 Mar 19
Sean Moran
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares1,500
Max PriceUS$6.67
BuyUS$9,93014 Mar 19
Yuval Cohen
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares1,530
Max PriceUS$6.49

Ownership Breakdown


Management Team

  • Sean Moran (61yo)

    Chief Financial Officer

    • Tenure: 5.4yrs
    • Compensation: US$1.24m
  • Mark Tepper (62yo)

    Co-Founder & Consultant

    • Tenure: 0.4yrs
    • Compensation: US$1.66m
  • Yuval Cohen (44yo)

    CEO & Director

    • Tenure: 5.4yrs
    • Compensation: US$3.57m
  • Barbara White (69yo)

    Chief Medical Officer

    • Tenure: 5.1yrs
    • Compensation: US$1.69m
  • Craig Millian (51yo)

    Chief Commercial Officer

    • Tenure: 0.6yrs
  • Scott Constantine

    Senior Director & Head of Clinical Operations

    • Tenure: 0yrs
  • Robert Discordia

    Chief Operating Officer

    • Tenure: 0yrs
  • Ted Jenkins

    Senior Director of Investor Relations & Communications

    • Tenure: 0yrs
  • Sergei Atamas

    Executive Director of Research

    • Tenure: 0yrs

Board Members

  • Chip Catlin (71yo)

    Director

    • Tenure: 5.1yrs
    • Compensation: US$213.62k
  • David Hochman (44yo)

    Director

    • Tenure: 5.8yrs
    • Compensation: US$205.20k
  • Alan Holmer (69yo)

    Chairman

    • Tenure: 5.4yrs
    • Compensation: US$238.71k
  • Yuval Cohen (44yo)

    CEO & Director

    • Tenure: 5.4yrs
    • Compensation: US$3.57m
  • Charles Serhan

    Member of Scientific Advisory Board

    • Tenure: 4.3yrs
  • George Kunos

    Member of Scientific Advisory Board

    • Tenure: 1yrs
  • Paris Panayiotopoulos (45yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$215.96k
  • Michael Knowles

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • John Jenkins (61yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$325.35k
  • Rachelle Jacques (47yo)

    Director

    • Tenure: 0.4yrs

Company Information

Corbus Pharmaceuticals Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Corbus Pharmaceuticals Holdings, Inc.
  • Ticker: CRBP
  • Exchange: NasdaqGM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$362.049m
  • Shares outstanding: 64.65m
  • Website: https://www.corbuspharma.com

Number of Employees


Location

  • Corbus Pharmaceuticals Holdings, Inc.
  • 500 River Ridge Drive
  • Norwood
  • Massachusetts
  • 2062
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRBPNasdaqGM (Nasdaq Global Market)YesNew Common SharesUSUSDOct 2014
337DB (Deutsche Boerse AG)YesNew Common SharesDEEUROct 2014
0SZILSE (London Stock Exchange)YesNew Common SharesGBUSDOct 2014

Biography

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 00:18
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.